Literature DB >> 15222571

Development of botulinum toxin therapy.

Alan B Scott1.   

Abstract

Justinius Kerner collected data on 230 cases of botulism in the 1820s, suggested the therapeutic use of toxin, and gave a remarkably complete and accurate description of clinical botulism: its symptoms, time course, and the physical findings that the tear fluid disappears, the skin is dry, the eye, gut, and somatic muscles are paralyzed, and mucus and saliva secretion is suppressed. These effects are the clinical targets of botulinum therapy today. Inspired by Drachman's use of toxin to safely paralyze the hind limb in chicks, we worked out the procedures for its safe medical application and licensure from 1972 to 1989, applying it first to correct strabismus, blepharospasm, leg muscle spasm, and torticollis. This list is now extended by others to well over 100 uses. For many years, blepharospasm patients returning for injection around the eyes and upper face would mention as a joke that they were "back to get the wrinkles out." Working in aesthetic dermatology and ophthalmology, Alistair and Jean Carruthers could envision the intentional cosmetic application of botulinum toxin, probably its greatest single use today.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222571     DOI: 10.1016/s0733-8635(03)00019-6

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  10 in total

1.  Characterization of some morphological parameters of orbicularis oculi motor neurons in the monkey.

Authors:  D W McNeal; J Ge; J L Herrick; K S Stilwell-Morecraft; R J Morecraft
Journal:  Neuroscience       Date:  2007-07-17       Impact factor: 3.590

Review 2.  From poison to remedy: the chequered history of botulinum toxin.

Authors:  F J Erbguth
Journal:  J Neural Transm (Vienna)       Date:  2007-04-26       Impact factor: 3.575

3.  An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection.

Authors:  Temeri D Wilder-Kofie; Carolina Lúquez; Michael Adler; Janet K Dykes; JoAnn D Coleman; Susan E Maslanka
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

4.  Sustained improvement of reading symptoms following botulinum toxin A injection for convergence insufficiency.

Authors:  Jon Peiter Saunte; Jonathan M Holmes
Journal:  Strabismus       Date:  2014-04-30

5.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

6.  Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a.

Authors:  Baskaran Thyagarajan; Natalia Krivitskaya; Joseph G Potian; Kormakur Hognason; Carmen C Garcia; Joseph J McArdle
Journal:  J Pharmacol Exp Ther       Date:  2009-08-04       Impact factor: 4.030

7.  Substance P is essential for maintaining gut muscle contractility: a novel role for coneurotransmission revealed by botulinum toxin.

Authors:  Cuiping Li; Maria-Adelaide Micci; Karnam S Murthy; Pankaj Jay Pasricha
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-03       Impact factor: 4.052

Review 8.  Therapeutic applications of botulinum neurotoxins in head and neck disorders.

Authors:  Ahmad Alshadwi; Mohammed Nadershah; Timothy Osborn
Journal:  Saudi Dent J       Date:  2014-12-13

9.  Botulinum toxin related research in maxillofacial plastic and reconstructive surgery.

Authors:  Tae-Geon Kwon
Journal:  Maxillofac Plast Reconstr Surg       Date:  2016-09-05

10.  Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity.

Authors:  Malene Rohrsted; Cecilie Bagi Nordsten; Per Bagi
Journal:  Nephrourol Mon       Date:  2012-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.